Last reviewed · How we verify
Standard dosage of Tacrolimus
Tacrolimus, marketed by Nuria Lloberas Blanch, is an established immunosuppressive agent with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and market presence, supported by its current marketed status. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Standard dosage of Tacrolimus |
|---|---|
| Also known as | Tacrolimus |
| Sponsor | NURIA LLOBERAS BLANCH |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tocilizumab in Lung Transplantation (PHASE2)
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
- US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia (PHASE2)
- Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies (PHASE2)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY) (PHASE4)
- A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) (PHASE3)
- Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard dosage of Tacrolimus CI brief — competitive landscape report
- Standard dosage of Tacrolimus updates RSS · CI watch RSS
- NURIA LLOBERAS BLANCH portfolio CI